An interventional study of Sentinel Node Biopsy and Limited Elective Neck Dissection in Mouth Neoplasms, Oral Cancers and Oral Squamous Cell Carcinoma (OSCC), sponsored by Tata Memorial Hospital. Recruiting at 3 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Tata Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Mouth Neoplasms with a site in India — 8 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · India.
Among the 23 studies in Mouth Neoplasms with a site in India, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 14th registered.
447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.
Browse Mouth Neoplasms studies →8 of the 23 studies in Mouth Neoplasms with a site in India are open now. Recruiting first, the newest first:
Kolhapur Cancer Centre - Cancer Centers of America · Sites in India
Ages 21–75
Kolhapur Cancer Centre - Cancer Centers of America · Sites in India
Ages 21–75
All India Institute of Medical Sciences, Jodhpur · Sites in India
Ages 18–75
Dr.Pankaj Chaturvedi · Sites in India
Ages 18–100
Banaras Hindu University · Sites in India
Ages 18–100
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 508 is above the median of 60 across 313 interventional studies indexed under Mouth Neoplasms.
Median enrollment 140 across the 22 interventional studies, 200 across the 1 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 23 have an industry lead sponsor. The 10 most frequent:
Tata Memorial Hospital is the lead sponsor of 99 studies on the registry; 21 are open to participants now.
Tata Memorial Hospital has 8 studies filed under Mouth Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Mouth Neoplasms with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06737822Phase 3All India Institute of Medical Sciences, JodhpurUpfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers: | 2027-10 |
| NCT04809324Dr.Pankaj ChaturvediGross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers | 2026-12 |
| NCT05969314Tata Memorial HospitalTo Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer | 2026-12-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Mouth Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.
The main questions it aims to answer are:
Participants will either undergo sentinel node biopsy followed by completion neck dissection if sentinel node is reported to be metastatic (SNB) or limited elective neck dissection where level IIb will be cleared only if level IIa is metastatic (limited END). The study will compare the outcomes in the two cohorts.
Based on the current literature, we know that elective neck dissection (END) is mandatory in clinically node-negative early oral cancers. However, this leads to overtreatment and morbidity in about 55-80% of patients. The emergence of recent level I evidence makes SNB the standard of care in this setting. However, its limitation of being a two-staged procedure, steep learning curve, the burden on resources, lack of infrastructure, short-lasting decrease in morbidity and lack of cost-effectiveness data limits its wide applicability. It is our routine departmental practice of performing limited neck dissection clearing level I-III/IV sparing level IIb which is cleared only if level IIa is metastatic. It is hypothesized that limited END would limit the morbidity of shoulder dysfunction and be a more feasible and cost-effective treatment option which could be a suitable alternative to SNB in this setting without compromising the survival outcomes. With this background, we propose to embark upon a phase III RCT comparing the oncologic outcomes and morbidity of SNB versus limited END. We hypothesize that limited END would have survival outcomes non-inferior, morbidity similar to SNB with higher cost-effectiveness.
Aims and objectives:
Aim To compare the survival outcomes, morbidity and cost-effectiveness of SNB versus limited END in node-negative early oral cancers
Primary objective
1) Overall survival
Secondary objectives
Exploratory objectives Blood and tumour tissue will be collected and banked for biomarker studies. Exploratory analyses will be conducted at a later date. Efforts may be directed to identify the biomarkers to predict nodal metastasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Sentinel Node Biopsy
Procedure: Limited Elective Neck Dissection
The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.
Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
Overall survival
Defined from the date of randomization to death due to any cause
Time frame: 3 years
Shoulder morbidity
It will be assessed using the neck dissection impairment index (NDII). The range of movement of the shoulder will also be assessed using a goniometer
Time frame: Longitudinally at preoperatively, 3 months, at 6 months, 12 months and 24 months of treatment
Neck nodal recurrence
Defined from the date of randomization to isolated neck node recurrence or death due to any cause
Time frame: 3 years
Disease free survival
Defined from the date of randomization to any recurrence (local, regional or distant metastasis) and second primary in the oral cavity
Time frame: 3 years
Health related Quality of life
Quality of life will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ C30 and QLQ HN35 instruments
Time frame: Longitudinally at preoperatively, 3 months, at 6 months, 12 months and 24 months of treatment
Adverse events related to the surgical procedure and lymphedema
Details of the intra and perioperative delay including injury to critical structures, chyle leak, haemorrhage, and head and neck lymphedema
Time frame: The lymphedema rating will be done at 3 months, at 6 months, 12 months and 24 months of treatment
Cost effectiveness
Based on direct cost comparison
Time frame: 3 years
Started Apr 2025 (actual). Primary completion is estimated for Apr 2032, 84 months after the start.
Of 98 non-industry interventional studies with no phase under Mouth Neoplasms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 97. This study's planned 84 months is above that.
Counting every sponsor, half of 99 studies reached it within 30 months; a quarter within 17 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Hospital